Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
Phase 1
Completed
- Conditions
- Advanced Hematological Disorders
- Interventions
- Drug: ORH-2014
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Orsenix LLC
- Target Recruit Count
- 12
- Registration Number
- NCT03048344
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
News
No news found